Infosys
INFY
10.55
0.00
0.00%
Infosys
US · INFY
#508 by market cap
Listed 1970
10.55
0.00
0.00%
Live - 5344 symbols - heartbeat 488s ago
· 2026-10-08 07:40
Pre-market
10.55
0.00%
After-hours
10.53
-0.19%
Overnight
10.53
-0.19%
- Market cap
- 42.73B
- P/E (TTM)i
- 13.02
- P/Bi
- 4.44
- EPSi
- 0.80
- Div yieldi
- 4.97%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on INFY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 9 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.6 percentage points.
Institutional ownership
- Held by institutions
- 68.49% +0.57pp
- Institutions
- 717 -9
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund49.22%
Public Company13.40%
Individual/Insider2.56%
Hedge Fund1.32%
Government1.23%
Sovereign Wealth Fund1.11%
Private Company0.87%
Government Pension Fund0.81%
Corporate Pension Plan0.27%
Other29.20%
Top holders as of 2026-05-20
Life Insurance Corporation of India
10.83% · 438.42M sh
BlackRock
4.97% · 201.19M sh
ICICI Prudential Asset Management Company Limited
4.39% · 177.65M sh
SBI Funds Management Limited
4.31% · 174.63M sh
Vanguard Capital Management, LLC
2.49% · 101.02M sh
Nandan Nilekani
2.48% · 100.47M sh
The Vanguard
2.44% · 98.91M sh
Nippon Life India Asset Management Limited
2.08% · 84.07M sh
HDFC Asset Management Company Limited
1.89% · 76.38M sh
UTI Asset Management Company Limited
1.64% · 66.44M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
33 filings tracked · 8 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| Nandan Nilekani | Chairperson | 2.48% |
| Salil Parekh | Chief Executive Officer | 0.04% |
| Shaji Mathew | Group Head of HR, Exec VP & Svc Offering Head of Fin Svcs, Healthcare, Ins and Life Sciences | 0.01% |
| Inderpreet Sawhney | Executive VP, Group General Counsel & Chief Compliance Officer | 0.01% |
| Jayesh Sanghrajka | Executive VP & Deputy CFO | 0.00% |
| Bobby Parikh | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-05-13 | Jayesh Sanghrajka | Executive VP & Deputy CFO | Open Market Disposition | -5,191 | $11.41 |
| 2026-05-13 | Inderpreet Sawhney | Executive VP, Group General Counsel & Chief Compliance Officer | Derivative Exercise and Sale | -6,845 | $0.00–0.12 |
| 2026-05-13 | Shaji Mathew | Group Head of HR, Exec VP & Svc Offering Head of Fin Svcs, Healthcare, Ins and Life Sciences | Open Market Disposition | -740 | $11.41 |
| 2026-05-12 | Inderpreet Sawhney | Executive VP, Group General Counsel & Chief Compliance Officer | Intent to Sell (Form 144) | -6,845 | $11.77 |
| 2026-05-07 | Salil Parekh | Chief Executive Officer | Derivative Exercise and Sale | -95,800 | $0.05–12.47 |
| 2026-05-01 | Salil Parekh | Chief Executive Officer | Other Derivative Acquisition | +13,273 | $5.00 |
| 2026-05-01 | Salil Parekh | Chief Executive Officer | Other Derivative Acquisition | +43,138 | $5.00 |
| 2026-05-01 | Salil Parekh | Chief Executive Officer | Other Derivative Acquisition | +230,621 | $5.00 |
| 2026-05-01 | Salil Parekh | Chief Executive Officer | Derivative Exercise and Retained | +148,094 | $0.05 |
| 2026-03-30 | Jayesh Sanghrajka | Executive VP & Deputy CFO | Other Derivative Acquisition | +2,441 | $0.05 |
| 2026-03-30 | Inderpreet Sawhney | Executive VP, Group General Counsel & Chief Compliance Officer | Other Derivative Acquisition | +4,880 | $0.00 |
| 2026-03-30 | Shaji Mathew | Group Head of HR, Exec VP & Svc Offering Head of Fin Svcs, Healthcare, Ins and Life Sciences | Other Derivative Acquisition | +1,830 | $0.05 |
| 2026-03-17 | Nandan Nilekani | Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Bobby Parikh | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Salil Parekh | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jayesh Sanghrajka | Executive VP & Deputy CFO | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Inderpreet Sawhney | Executive VP, Group General Counsel & Chief Compliance Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Shaji Mathew | Group Head of HR, Exec VP & Svc Offering Head of Fin Svcs, Healthcare, Ins and Life Sciences | Initial Statement of Beneficial | 0 | -- |
| 2026-03-11 | Inderpreet Sawhney | Executive VP, Group General Counsel & Chief Compliance Officer | Intent to Sell (Form 144) | -6,550 | $13.77 |
| 2026-02-14 | Inderpreet Sawhney | Executive VP, Group General Counsel & Chief Compliance Officer | Derivative Exercise and Retained | +4,745 | $0.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:40:06 · For reference only, not investment advice and not tailored to your situation.